top of page
  • Writer's pictureMuvon

MUVON featured by Nature Biotechnology

MUVON Therapeutics was featured by Nature as one of the companies leading the way with innovative treatments for stress urinary incontinence, showcasing the immense potential in women's health advancements.

Despite women driving 80% of healthcare spending, women's health receives less than 1% of biopharma funding. Deana Mohr, CEO of MUVON Therapeutics, highlights the issue: "Investors often see women’s health as a niche 'wellness' sector rather than an area of high unmet medical need." This misperception neglects critical medical conditions affecting millions of women. It's time to reclassify women's health as a priority in medical research and investment. 

Read the full article here.

12 views0 comments


bottom of page